132 related articles for article (PubMed ID: 16224590)
1. Reductase activity of 17beta-hydroxysteroid oxidoreductase in prostatic tumors of different histological structure.
Degtyar VG; Babkina TV; Kazantseva IA; Morozov AP; Trapeznikova MF; Kushlinskii NE
Bull Exp Biol Med; 2005 Jun; 139(6):715-7. PubMed ID: 16224590
[TBL] [Abstract][Full Text] [Related]
2. Structure-function aspects and inhibitor design of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3).
Penning TM; Burczynski ME; Jez JM; Lin HK; Ma H; Moore M; Ratnam K; Palackal N
Mol Cell Endocrinol; 2001 Jan; 171(1-2):137-49. PubMed ID: 11165022
[TBL] [Abstract][Full Text] [Related]
3. 5alpha-reductase and 17beta-hydroxysteroid dehydrogenase expression in epithelial cells from hyperplastic and malignant human prostate.
Délos S; Carsol JL; Fina F; Raynaud JP; Martin PM
Int J Cancer; 1998 Mar; 75(6):840-6. PubMed ID: 9506528
[TBL] [Abstract][Full Text] [Related]
4. Characterization of 17beta-hydroxysteroid dehydrogenase isoenzyme expression in benign and malignant human prostate.
Elo JP; Akinola LA; Poutanen M; Vihko P; Kyllönen AP; Lukkarinen O; Vihko R
Int J Cancer; 1996 Mar; 66(1):37-41. PubMed ID: 8608963
[TBL] [Abstract][Full Text] [Related]
5. 5α-reductase type 3 enzyme in benign and malignant prostate.
Titus MA; Li Y; Kozyreva OG; Maher V; Godoy A; Smith GJ; Mohler JL
Prostate; 2014 Feb; 74(3):235-49. PubMed ID: 24150795
[TBL] [Abstract][Full Text] [Related]
6. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
[TBL] [Abstract][Full Text] [Related]
7. Androgen formation and metabolism in the pulmonary epithelial cell line A549: expression of 17beta-hydroxysteroid dehydrogenase type 5 and 3alpha-hydroxysteroid dehydrogenase type 3.
Provost PR; Blomquist CH; Godin C; Huang XF; Flamand N; Luu-The V; Nadeau D; Tremblay Y
Endocrinology; 2000 Aug; 141(8):2786-94. PubMed ID: 10919264
[TBL] [Abstract][Full Text] [Related]
8. Metabolism of androgens in human hyperplastic prostate: evidence for a differential localization of the enzymes involved in the metabolism.
Abalain JH; Quemener E; Carre JL; Simon B; Amet Y; Mangin P; Floch HH
J Steroid Biochem; 1989; 34(1-6):467-71. PubMed ID: 2483221
[TBL] [Abstract][Full Text] [Related]
9. Stromal 5 alpha-reductase activity is elevated in benign prostatic hyperplasia.
Wilkin RP; Bruchovsky N; Shnitka TK; Rennie PS; Comeau TL
Acta Endocrinol (Copenh); 1980 Jun; 94(2):284-8. PubMed ID: 6158242
[TBL] [Abstract][Full Text] [Related]
10. Changes in the metabolism of dihydrotestosterone in the hyperplastic human prostate.
Isaacs JT; Brendler CB; Walsh PC
J Clin Endocrinol Metab; 1983 Jan; 56(1):139-46. PubMed ID: 6183287
[TBL] [Abstract][Full Text] [Related]
11. Discrimination between normal, hyperplastic and malignant human prostatic tissues by enzymatic profiles.
Brendler CB; Follansbee AL; Isaacs JT
J Urol; 1985 Mar; 133(3):495-501. PubMed ID: 3856037
[TBL] [Abstract][Full Text] [Related]
12. Androgen metabolism in sebaceous glands from subjects with and without acne.
Thiboutot D; Gilliland K; Light J; Lookingbill D
Arch Dermatol; 1999 Sep; 135(9):1041-5. PubMed ID: 10490108
[TBL] [Abstract][Full Text] [Related]
13. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
Habib FK; Ross M; Tate R; Chisholm GD
Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
[TBL] [Abstract][Full Text] [Related]
14. Cellular regulation of the metabolism of androgens in rat oral mucosa: I. Effect of medroxyprogesterone acetate (MPA) on the soluble supernatant (cytosol) activating microsomal delta4-3-ketosteroid-5alpha-reductase and 17beta-hydroxysteroid oxidoreductase enzyme systems.
Vittek J; Rappaport SC; Gordon GG; Southren AL
J Dent Res; 1978; 57(11-12):1016-8. PubMed ID: 281334
[TBL] [Abstract][Full Text] [Related]
15. Androgen metabolism in the human prostatic cancer cell line LNCaP.
Negri-Cesi P; Motta M
J Steroid Biochem Mol Biol; 1994 Oct; 51(1-2):89-96. PubMed ID: 7947355
[TBL] [Abstract][Full Text] [Related]
16. Androgen metabolism in the epithelial and stromal components of the human hyperplastic prostate.
Habib FK; Tesdale AL; Chisholm GD; Busuttil A
J Endocrinol; 1981 Oct; 91(1):23-32. PubMed ID: 6170712
[TBL] [Abstract][Full Text] [Related]
17. Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer.
Thomas LN; Lazier CB; Gupta R; Norman RW; Troyer DA; O'Brien SP; Rittmaster RS
Prostate; 2005 May; 63(3):231-9. PubMed ID: 15538746
[TBL] [Abstract][Full Text] [Related]
18. Investigation of the In Vitro and In Vivo efficiency of RM-532-105, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, in LAPC-4 prostate cancer cell and tumor models.
Kenmogne LC; Roy J; Maltais R; Rouleau M; Neveu B; Pouliot F; Poirier D
PLoS One; 2017; 12(2):e0171871. PubMed ID: 28182747
[TBL] [Abstract][Full Text] [Related]
19. Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones.
Penning TM; Burczynski ME; Jez JM; Hung CF; Lin HK; Ma H; Moore M; Palackal N; Ratnam K
Biochem J; 2000 Oct; 351(Pt 1):67-77. PubMed ID: 10998348
[TBL] [Abstract][Full Text] [Related]
20. 5alpha-reductase activity in the prostate.
Steers WD
Urology; 2001 Dec; 58(6 Suppl 1):17-24; discussion 24. PubMed ID: 11750244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
